InterMune Plans Pirfenidone Pulmonary Fibrosis Phase III Study In 2006
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
InterMune's pivotal trials of pirfenidone will be the first Phase III studies of an idiopathic pulmonary fibrosis drug to use the primary endpoint of lung function as measured by change in forced vital capacity